Search

Displaying results 9751 - 9760 of 10000 in total
  1. Drug

    LY2828360

    go.drugbank.com/drugs/DB16074
    Investigational

    LY2828360 is under investigation in clinical trial NCT01319929 (A Study of LY2828360 in Patients With Osteoarthritic Knee Pain).

  2. Drug

    Dopastatin

    go.drugbank.com/drugs/DB16144
    Investigational

    Dopastatin is under investigation in clinical trial NCT04335357 (TBR-760 in Adult Patients With Non-functioning Pituitary Adenomas).

  3. Drug

    Ibezapolstat

    go.drugbank.com/drugs/DB16189
    Investigational

    Ibezapolstat is under investigation in clinical trial NCT04247542 (ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection).

  4. Drug

    Autologous DNP-conjugated tumour vaccine

    go.drugbank.com/drugs/DB17361
    Investigational

    Autologous DNP-conjugated tumour vaccine, or melanoma vaccine, is an investigational autologous cell vaccine technology for melanoma.[A254806]

  5. Drug

    Trotabresib

    go.drugbank.com/drugs/DB17421
    Investigational

    Trotabresib is an oral, potent, and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.

  6. Drug

    Enoblituzumab

    go.drugbank.com/drugs/DB15017
    Investigational

    Enoblituzumab is under investigation in clinical trial NCT02982941 (Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors).

  7. Drug

    Agerafenib

    go.drugbank.com/drugs/DB15068
    Investigational

    Agerafenib is under investigation in clinical trial NCT03052569 (Expanded Access to RXDX-105 for Cancers With RET Alterations).

  8. Drug

    Pittsburgh Compound B

    go.drugbank.com/drugs/DB15161
    Investigational

    Pittsburgh Compound B is under investigation in clinical trial NCT01723553 (Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD).

  9. Drug

    MAX-40279

    go.drugbank.com/drugs/DB15191
    Investigational

    MAX-40279 is under investigation in clinical trial NCT03412292 (MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)).

  10. Drug

    EC-0652

    go.drugbank.com/drugs/DB15340
    Experimental

    EC-0652 is under investigation in clinical trial NCT02202447 (Phase 1 of EC1169 In Patients With Recurrent MCRPC).